First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
Located in Changshu, the new site will manufacture wound care products for the Chinese market, supporting faster response times and greater supply chain resilience. It reflects Mölnlycke's ambition to manufacture products closer to where they are sold, while drawing on the same quality standards, operational excellence and expertise that connects its global operations network.
"The completion of the factory reflects years of planning, collaboration and dedication from teams across Mölnlycke. We are now preparing for the next phase as we work towards commercial production," says Antti Wiksten, General Manager of the Changshu factory, "This is a significant milestone for Mölnlycke and an important step in our long-term commitment to China.”
The new facility joins Mölnlycke’s global manufacturing network, which spans 16 sites in 11 countries across Europe, Asia, the Middle East and the Americas. More than a collection of individual factories, this network of sites operates as one connected system, with shared processes, expertise and standards that enable Mölnlycke to meet growing demand, scale capabilities efficiently and respond with greater agility to changing customer and market needs.
A global Mölnlycke operations standard provides the backbone for this network, helping to ensure that all sites operate with the same expectations for quality, compliance, safety, operational excellence and continuous improvement, while still allowing local teams to adapt to local regulations, customer needs and market conditions.
"Our ambition is to combine Mölnlycke's global expertise with strong local capabilities," says Wiksten. "Changshu is a great example of how we are building on our shared operating standard to support growth in China while strengthening our ability to serve customers locally and effectively."
Beyond demonstrating Mölnlycke's long-term commitment to China, Changshu also shows how the company is using its connected manufacturing network as a platform for growth: transferring knowledge across sites, building local capacity in important markets and applying one global standard to deliver reliable, high-quality wound care solutions to healthcare professionals and patients.
Latest news
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China.